Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
See All Experts
story of the week
Published in Oncology and
2 other channels

Journal Scan / Research · February 28, 2019

Pembrolizumab Plus Axitinib vs Sunitinib for Advanced RCC

The New England Journal of Medicine

 

 Save  Recommend
 Share

Additional Info

The New England Journal of Medicine
Pembrolizumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
N. Engl. J. Med 2019 Feb 16;[EPub Ahead of Print], BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, B Alekseev, D Soulières, B Melichar, I Vynnychenko, A Kryzhanivska, I Bondarenko, SJ Azevedo, D Borchiellini, C Szczylik, M Markus, RS McDermott, J Bedke, S Tartas, YH Chang, S Tamada, Q Shou, RF Perini, M Chen, MB Atkins, T Powles

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated